reference/32403052

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/32403052

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial
endingPage	e15
issn	1083-7159 1549-490X
issueIdentifier	3
pageRange	241-e15
publicationName	The Oncologist
startingPage	241
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b89c85ac6ae0356a6bc034e107cf2653
bibliographicCitation	Benson AB, Wainberg ZA, Hecht JR, Vyushkov D, Dong H, Bendell J, Kudrik F. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma. Oncologist. 2017 Mar;22(3):241–e15. PMID: 28246206; PMCID: PMC5344644.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_843e21b24de443920e567e04af072212 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd5059d934f5c8686f875d669afdb17e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a99c32fa653a2f252b94190e3c56535b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_02a6177a6176f7fa3a0edfee3ed9134d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d4d8890e908d284012523ce977871ebb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7c3f0a9b19b0495e7def6d41a1ac0617 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_431e8e1f32ad8a8ac53adcf17c3c711c
date	2017-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC5344644 https://pubmed.ncbi.nlm.nih.gov/28246206 https://doi.org/10.1634/theoncologist.2017-0024
isPartOf	https://portal.issn.org/resource/ISSN/1083-7159 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21392 https://portal.issn.org/resource/ISSN/1549-490X
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma
discusses	http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0376295 http://id.nlm.nih.gov/mesh/M0000920 http://id.nlm.nih.gov/mesh/M0016932 http://id.nlm.nih.gov/mesh/M000625587 http://id.nlm.nih.gov/mesh/M0005997 http://id.nlm.nih.gov/mesh/M0305005
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D003841Q000031 http://id.nlm.nih.gov/mesh/D000230Q000188 http://id.nlm.nih.gov/mesh/D010190Q000188 http://id.nlm.nih.gov/mesh/D000594Q000037 http://id.nlm.nih.gov/mesh/D061067Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000230Q000473 http://id.nlm.nih.gov/mesh/D003841Q000008 http://id.nlm.nih.gov/mesh/D007074Q000008 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D000230Q000235 http://id.nlm.nih.gov/mesh/D010919 http://id.nlm.nih.gov/mesh/D010190Q000473 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D005109Q000187 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D010190Q000235 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D000594Q000235 http://id.nlm.nih.gov/mesh/D000971Q000008 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D010190 http://id.nlm.nih.gov/mesh/D003841Q000009 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D061067Q000009 http://id.nlm.nih.gov/mesh/D018572
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_694b47acac407eb6a961a33fb2969202 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6795 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID4017

Total number of triples: 73.